AlphaCentric Advisors LLC Has $503,000 Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

AlphaCentric Advisors LLC cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 83.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,684 shares of the company’s stock after selling 18,816 shares during the quarter. AlphaCentric Advisors LLC’s holdings in Neurocrine Biosciences were worth $503,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Capital Performance Advisors LLP grew its holdings in Neurocrine Biosciences by 1,101.4% during the 4th quarter. Capital Performance Advisors LLP now owns 1,730 shares of the company’s stock worth $236,000 after acquiring an additional 1,586 shares during the period. Sheaff Brock Investment Advisors LLC boosted its position in shares of Neurocrine Biosciences by 11.7% during the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 2,499 shares of the company’s stock valued at $341,000 after purchasing an additional 261 shares in the last quarter. Principal Securities Inc. grew its stake in Neurocrine Biosciences by 24.3% during the fourth quarter. Principal Securities Inc. now owns 1,382 shares of the company’s stock worth $189,000 after purchasing an additional 270 shares during the period. Autumn Glory Partners LLC bought a new stake in Neurocrine Biosciences in the fourth quarter worth approximately $273,000. Finally, Asset Management One Co. Ltd. boosted its holdings in shares of Neurocrine Biosciences by 1.7% during the 4th quarter. Asset Management One Co. Ltd. now owns 70,431 shares of the company’s stock worth $9,821,000 after buying an additional 1,201 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 65,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the completion of the transaction, the chief executive officer now directly owns 135,392 shares of the company’s stock, valued at $19,157,968. This represents a 32.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kevin Charles Gorman sold 5,844 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total value of $681,936.36. Following the completion of the sale, the director now owns 521,618 shares in the company, valued at approximately $60,867,604.42. The trade was a 1.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 236,600 shares of company stock worth $34,348,261 in the last quarter. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $115.02 on Monday. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The firm’s 50-day simple moving average is $137.83 and its 200 day simple moving average is $130.46. The stock has a market cap of $11.65 billion, a PE ratio of 34.96 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. As a group, analysts predict that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on NBIX. Canaccord Genuity Group dropped their target price on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Bank of America dropped their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a report on Friday, February 7th. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Guggenheim decreased their target price on Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Finally, HC Wainwright cut their price target on Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $166.90.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.